Amylyx Pharmaceuticals (AMLX) vs Organon (OGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Amylyx Pharmaceuticals (AMLX) has outperformed Organon (OGN) over the past year, gaining 103.3% versus a gain of 30.1%. Organon is the larger company by market cap ($3.62 billion vs $3.44 billion), about 1.1 times the size. Organon pays a dividend yielding 0.58%, while Amylyx Pharmaceuticals does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMLX | OGN |
|---|---|---|
| Share price | $27.43 | $13.79 |
| Market cap | $3.44B | $3.62B |
| 1-day change | -2.18% | +0.36% |
| YTD return | +127.07% | +92.33% |
| 1-year return | +103.34% | +30.09% |
| 5-year return | — | -60.48% |
| P/E ratio (TTM) | — | 17.68 |
| Forward P/E | — | 3.81 |
| EPS (TTM) | $-1.38 | $0.78 |
| Dividend yield | 0.00% | 0.58% |
| Annual dividend | $0.00 | $0.08 |
| 52-week high | $41.14 | $13.79 |
| 52-week low | $10.83 | $5.69 |
| Distance from 52-week high | -33.33% | 0.00% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +54.43% | -18.42% |
| Average volume | 2.33M | 2.65M |
| Shares outstanding | 125.51M | 262.61M |
| Employees | 136 | 10,000 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations | Drug Manufacturers - General |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AMLX has outperformed OGN by 73.2 percentage points over the past year.
- The two companies sit in different sectors: Amylyx Pharmaceuticals in Health Care and Organon in Healthcare.
About Amylyx Pharmaceuticals
AMLX stock →Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism.
Health Care · Biotechnology: Pharmaceutical Preparations · 136 employees
About Organon
OGN stock →Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally.
Healthcare · Drug Manufacturers - General · 10,000 employees
AMLX vs OGN FAQ
Which is bigger, Amylyx Pharmaceuticals or Organon?
Organon (OGN) is larger, with a market capitalization of $3.62B compared with $3.44B for Amylyx Pharmaceuticals (AMLX).
Which stock has performed better over the past year, AMLX or OGN?
AMLX returned +103.34% over the past 12 months, compared with +30.09% for OGN (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Amylyx Pharmaceuticals or Organon?
Organon pays a dividend yielding 0.58%, while Amylyx Pharmaceuticals does not currently pay a regular dividend.
Are Amylyx Pharmaceuticals and Organon in the same industry?
No. Amylyx Pharmaceuticals is in the Health Care sector, while Organon is in Healthcare.